AKT1 and esophageal cancer: In this study, we discovered that apatinib inhibited the growth of esophageal cancer and sensitized tumors to cisplatin by deactivating the Akt/β-catenin pathway, which provided a theoretical basis for apatinib as a potential therapeutic strategy for esophageal cancer.